晚期非小细胞肺癌化疗疗效分析与化疗敏感性预测

《晚期非小细胞肺癌化疗疗效分析与化疗敏感性预测》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、第三军医大学硕士学位论文Kaplan-Meiersurvivalanalysesandlog-ranktest．9．q,c—MIBlwereperformedin19advancedNSCLCpatientswithinaweekofpre-chemotherapy，earlyimageanddelayimageweretookin20rainand150rain,respectively．Then,theywerechosetobegivenregimensofTP、GP、NP、DP．c—MIBISPECTqua

2、litativeanalysiswasdiagnosedbymorethantwonuclearmedicinetechnologists，radioactiveconcentrationisdeterminationcriteria．Quantitativeanalysisbasedon99rnTc-MIBIuptakebytumor．Usingaratiooftheaveragecountsinthelesiontothoseinthecontralateralnormalregionontheearly(T／

3、Ne)anddelayed(T／Nd)SPECTimagesandretentionindexfROdefinedasthepercentageofchangein帅rc-1订mIuptake，Wascalculatedusing【(T／Nd-T厂Ne)／T／Ne]x100％．therelationshipbetweenT／Ne、T／Nd、砒％andresponseofchemotherapy,clinicalfactorandresponseofchemotherapywereassessedbytheIndep

4、endent—SamplesTTestforstatisticalanalysis．Probabilityvalues<0．05wereconsideredsignificant．Results1．Treatmenteffectsoffourcisplatin=basedregimell$foradvancedNSCLC(1)Overallresponserate(ORR)were34．9％．squamouscarcinomaandadenocarcinoma’SORRwere38．3％and30．6％,respe

5、ctively．InTP、GP、NP、DPregimen’sgroups，squamouscarcinoma’SORRwere41．7％、44．O％、34．8％、31．8％，mediansurvivaltime(MST)were12．1、12．3、11．7、11．8months，Timetoprogression(TTP)were4．4、4．5、3．1、4．4months，1-yearsurvivalratewere45．O％、44．0％、34．9％、36．4％respectively；adenocarcinoma

6、’SORRwere27．8％、25．O％、40．O％、28．6％，MSTwere11．2、11．1、11．5、10．4months；TIPwere3．7、3．2、4．0、4．7months，1-yearsurvivalratewere33．3％、30．O％、35．O％、35．7％respectively．ORR、MST、TTP、1-yearsurvivalratehaven’tsignificantdifferencesintwogroups(P>O．05)．Differentclinicalstageanddif

7、ferentclinicalfactorcouldn’tinfluencetreatmenteffects．(胗0．05)．(2)Themajoradversereactionsweremyelo—suppression、nausea、vomiting、phlebitis、alopecia．Therewerehi业estincidenceofthrombocytopenia(51．1％)inGPcomparedtoothergroups，especiallyIII。、IV。thrombocytopenia(24．4

8、％)inGP(P<0．05)．Theincidenceofnausea、vomitinginNP(37．2％)issignificanthigherthanothers(P